Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Metabolic Rewiring
Background
KRAS mutations are highly prevalent in lung cancer, yet existing KRASG12C inhibitors often face limited efficacy due to rapid metabolic adaptations. These adaptations include enhanced glutathione (GSH) metabolism and increased glycolysis, which contribute to drug resistance. Glutathione S-transferase zeta 1 (GSTZ1) is a metabolic enzyme known to regulate cell metabolism, but its specific role in KRAS-driven lung cancer and its contribution to therapeutic resistance have remained largely unexplored, representing a critical gap in current treatment strategies.
Study Design
Researchers investigated the role of GSTZ1 in KRASG12C-mutant non-small cell lung cancer (NSCLC) cells. They previously showed that targeting GSTZ1 significantly enhanced the efficacy of FDA-approved KRASG12C inhibitors. This study further explored the underlying mechanisms by performing untargeted metabolomics on NSCLC cells following GSTZ1 ablation. Additionally, they used pharmacologic inhibition of GSH synthesis and glucose uptake to mimic the effects of GSTZ1 targeting, assessing their impact on cell sensitization and key signaling pathways.
Results
Targeting GSTZ1 in KRASG12C-mutant NSCLC cells led to significant alterations in both GSH and glycolytic pathways. Specifically, untargeted metabolomics revealed lowered lactate levels and increased oxidized GSH following GSTZ1 ablation. These metabolic shifts were accompanied by crucial changes in cellular signaling: increased AMPK phosphorylation and reduced AKT phosphorylation, both key mediators in the response to KRASG12C inhibition. Pharmacologic inhibition of GSH synthesis and glucose uptake successfully mimicked the sensitizing effects observed with GSTZ1 targeting. This data strongly suggests that GSTZ1 is a critical mediator of drug resistance.
Targeting GSTZ1 disrupts metabolic and signaling pathways, making KRASG12C-mutant NSCLC cells more vulnerable to KRAS-directed treatments.
Key Findings
- Targeting GSTZ1 sensitized KRASG12C-mutant NSCLC cells to KRASG12C inhibitors.
- GSTZ1 ablation significantly altered GSH and glycolytic pathways, leading to lowered lactate and increased oxidized GSH.
- Metabolic shifts were accompanied by increased AMPK phosphorylation and reduced AKT phosphorylation.
- Pharmacologic inhibition of GSH synthesis and glucose uptake mimicked GSTZ1 targeting effects.
- GSTZ1 acts as a mediator of drug resistance, making it a potential therapeutic target.
Why It Matters
This research identifies GSTZ1 as a novel and promising complementary target to enhance the efficacy of KRASG12C inhibitors in NSCLC. For clinicians and biohackers, this suggests that combining KRASG12C inhibitors with agents that target GSTZ1 or disrupt GSH and glycolysis could overcome current resistance mechanisms. This finding supports rational combination strategies that exploit metabolic vulnerabilities, potentially leading to improved patient outcomes in KRAS-mutant lung cancer. While currently in vitro, this work lays the groundwork for developing new therapeutic protocols that integrate metabolic targeting with existing precision oncology approaches.
gstz1
krasg12c
nsclc
lung-cancer
glutathione-metabolism
glycolysis